secwatch.observer — SEC 8-K summary
======================================

Issuer:     NORTHWEST BIOTHERAPEUTICS INC (NWBO)
CIK:        0001072379
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001104659-24-056424
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Northwest Biotherapeutics enters $11M loan agreement with Streeterville Capital
-------------------------------------------------------------------------------

- Loan principal of $11,005,000; maturity 22 months; repayments begin Dec 26, 2024.
- 14 equal monthly installments at 110% of pro rata plus accrued interest (8% per annum).
- 10% original issue discount; prepayment allowed with 10% charge.
- Proceeds fund business ops, construction of first grade C lab in Sawston UK, long lead-time equipment, Flaskworks prep.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1072379/000110465924056424/0001104659-24-056424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1072379/000110465924056424/tm2413348d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-056424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer